Arcus Biosciences, Inc. Operating Income Loss

• Arcus Biosciences, Inc. showed a decrease of -17.0% in Operating Income Loss from 2024 to 2025.
• This data is from Arcus Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), Arcus Biosciences, Inc.'s Operating Income Loss has declined by 2,023.0%.
• Historical annual values: Fiscal year 2025: -$386.00 million | Fiscal year 2024: -$330.00 million | Fiscal year 2023: -$340.00 million | Fiscal year 2022: -$280.00 million | Fiscal year 2021: $54.00 million | Fiscal year 2020: -$124.00 million | Fiscal year 2019: -$88.71 million | Fiscal year 2018: -$54.86 million | Fiscal year 2017: -$53.44 million | Fiscal year 2016: -$18.18 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026